tbuckley/cabot-search huggingface dataset:
Population-wide patterns of care in mantle cell lymphoma in Australia: An analysis of the pharmaceutical benefits scheme dataset.
Authors: Constantine Si Lun Tam, Fei-Li Zhao, Tom Liu, Raj Gauba, Shu Chuen Li, Boxiong Tang
Journal: Journal of Clinical Oncology (2022)

e19587 Background: The treatment landscape in patients with mantle cell lymphoma (MCL) is changing with the introduction of Bruton’s tyrosine kinase inhibitors (BTKis) and bendamustine in Australia. We sought to analyze the practice impact of the introduction of publicly funded novel agents in MCL. The objective of this study was to describe the evolving treatment patterns of Australian patients with MCL over the last 10 years using population-wide prescription records. Methods: Patients who initiated a treatment for MCL between 01/01/2011 and 07/31/2021 were extracted from the Services Australia 10% Pharmaceuticals Benefits Scheme (PBS) dataset, which includes the dispensing records for 10% of the Australian population. This dataset captures all publicly funded treatments in Australia. The index date was defined as the commencement of any drug for MCL. First-line (1L) therapy was defined as the first treatments prescribed for MCL. A patient was defined as relapsed/refractory (R/R) if they had commenced a drug which was in a different therapeutic category, or if they re-started the same regimen after a gap of more than 180 days. Descriptive analyses were conducted to examine the use of treatment regimens for the overall 10-year population by line of therapy. Analyses by calendar year were also performed to assess the changes in the treatment patterns. Results: Overall, 241 patients with MCL were identified over the study period. The majority of patients were male (68.4%), age &gt; 60 years (84.9%), and most being aged 70-79 years (42.1% of total). Many patients were receiving comedications at baseline, including antihypertensives (44.1%), anticoagulants (14.5%), and/or antipsychotics or antidepressants (12.5%). In the overall population (2011-2021), the majority of patients had received 1L treatment with bendamustine-rituximab (BR, 53.9%), rituximab plus other regimens (27.6%), or rituximab monotherapy (11.2%). The most commonly used regimens in R/R patients at any subsequent episode of treatment included BTKi (66.3%), rituximab monotherapy (52.8%) or rituximab plus other regimens (31.5%). A trend in adoption of novel agents was observed throughout the years following their PBS listing. Analysis by calendar year showed that from 2011 to 2020 for 1L therapy, the use of BR increased from 0% to 50% and use of rituximab-containing regimen except BR decreased from 100% to 16.7%; use of BTKi increased in R/R patients from 0% to 74.7%. Conclusions: MCL treatment patterns have significantly changed in Australia since the introduction of BTKis and bendamustine-containing regimens. The use of rituximab-containing regimens except BR in 1L MCL has decreased and use of BTKis in R/R patients has increased.
Sensitive detection of pancreatic adenocarcinoma using plasma cell-free DNA methylomes.
Authors: Peiyao Nie, Fang Lv, Shuying He, Tiancheng Han, Shunli Yang, Li Suxing, Dan Liu, Ying Yang, Yulong LI, Yu S. Huang, Yuanyuan Hong, Weizhi Chen, Jianing Yu, Yongkun Sun
Journal: Journal of Clinical Oncology (2022)

e16277 Background: Cell-free DNA (cfDNA) methylation, fragmentation patterns, chromosome instability, and chromatin accessiblity have been previously shown to be valid plasma biomarkers for non-invasive cancer detection. However, conventional whole-genome bisulfite sequencing (WGBS) is unable to simultaneously profile all these biomarkers due to bisulfite-induced DNA damages. Here we developed a machine learning approach to comprehensively integrate multiple types of cancer genomic markers from enzyme-conversion-based low-pass whole-methylome sequencing (WMS) of plasma cfDNA to non-invasively detect pancreatic adenocarcinoma. Methods: Plasma cfDNA sampels from 139 cancer patients and 568 healthy individuals were collected and were split into the discovery and independent testing cohort. The discovery cohort includes 99 cancer patients and 398 healthy individuals and the independent testing cohort includes 40 cancer patients and 170 healthy individuals. Whole methylome sequencing (WMS) libraries were generated from enzymatically converted cfDNA and were subsequently paired-end sequenced at ̃2X coverage. The genome-wide methylation density, fragmentation fingerprints, chromosome instability, and chromatin accessibility were extracted from the WMS data and individually modelled via machine learning methods such as SVM, LR, GBDT, random forest. The final predictive model is an ensemble model integrating all uni-modal models. All models were trained and fitted on the discovery cohort. Results: Data of different modalities provide complementary information in separating the cancer patients from the healthy individuals. Unsupervised clustering of the individuals showed clear separation between cancer patients and healthy individuals. The final predictive model achieved AUC =0.982 in the discovery cohort and AUC =0.986 in the independent testing cohort. Under a specificity of 96.23% (CI: 87% - 88%), sensitivity was 95% (CI: 93% - 96%) in the independent testing cohort. Separating the cancer patients into different stages, we found that the detection power is usuaul lower for early-stage cancer patients. Conclusions: These results demonstrate the first proof of principle on the feasibility of integrating multiple genomic cancer markers to non-invasively detect pancreatic adenocarcinoma from WMS plasma cell-free DNA. A large prospective cohort study is planned to further validate its clinical performance.
The risk of Von Hippel-Lindau disease according to individual sporadic cancer in a multidisciplinary program: External validation of the VHL Alliance guidelines for genetic referral
Authors: A. Larcher, G. Fallara, I. Rowe, F. Belladelli, O. Iliopoulos, C. Doglioni, R. Lucianò, G. Casari, P. Carrera, M.G. Patricelli, A. Falini, F. De Cobelli, P. Mortini, J. Capitanio, M. Bailo, F. Bandello, R. Lattanzio, M. Falconi, S. Partelli, F. Muffatti, A. Necchi, F. Montorsi, U. Capitanio, A. Salonia
Journal: European Urology (2022)
Hematology/oncology outpatient perspectives on telehealth one year into the COVID-19 pandemic.
Authors: Anne Hudson Blaes, Patricia Jewett, Shernan Holtan, Bruce Lindgren, Jane Hui, Alexander Albert Boucher
Journal: Journal of Clinical Oncology (2022)

1594 Background: Telehealth use expanded during the COVID-19 pandemic, but few studies have explored patient perspectives on it after the initial months. Using mixed methods, we aimed to understand patient telehealth perspectives and to examine for whom telehealth is less optimal. Methods: A modified Telemedicine Satisfaction and Usefulness Questionnaire (TSUQ) for hematology/oncology outpatient care was sent to patients ≥18 years old within the M Health Fairview Masonic Cancer Clinic with ≥1 prior telehealth visit (phone and/or video). Two focus groups were also conducted. We summarized cohort characteristics and views on telehealth. We dichotomized selected TSUQ items (measured on a 1-5 scale) and evaluated them using logistic regression, adjusted for age (&lt;65 years, ≥65 years), gender, race (White, other), income (&lt;$50,000, $50,000-99,000, ≥$100,000, prefer not to say), education (no college degree, at least college degree), and having cancer (yes, no). Focus group data were analyzed qualitatively. Results: Of 7848 invitations, 588 surveys were completed (7.5% response rate). For respondents, 71% were female, 68.7% married/partnered, 90.6% identified as White, and 36.1% had a graduate/professional degree with an annual salary ≥$150,000 (21%). Most had cancer (73.3%) but were not currently receiving treatment (36.5%); 40% each had employer-based insurance or Medicare. Focus group members (n = 16) were chosen from a demographic mix of 121 volunteers. Most survey respondents found telehealth satisfactory [mean 3.8 ± standard deviation (SD) 0.9] and easy to use (mean 3.4 ± SD 0.9), 72.2% found it convenient, and 82.2% agreed that it saved time. Most (78.6%) would be happy with a combination of telehealth and in-person care going forward, but those with cancer were less likely to prefer future telehealth care (adjusted odds ratio [OR] 0.52, 95% confidence interval [CI] 0.34 - 0.81). Being male and having lower incomes were associated with greater telehealth satisfaction, (male vs. female, OR 1.68, 95% CI 1.00 - 2.83), income &lt;$50,000 vs. ≥$100,000 (OR 2.47, 95% CI 1.16 - 5.28). Focus group members reported between 1 - 30 telehealth visits (overall care range 8 months - 30 years). Views on telehealth mirrored survey results. Time saved and reduced exposure risk were beneficial, especially for those in rural settings and for those seeing genetic counselors or palliative care. However, concerns were voiced about fewer in-person interactions, communication gaps, and provider style variability. Conclusions: Our findings show that oncology patients prefer care in person despite telehealth’s benefits. Additional work is needed to ascertain the optimal, and possibly patient subgroup-specific, combination of in-person and telehealth in ambulatory hematology/oncology care to manage the needs of different populations.
Analysis of a post covid multi-disciplinary meeting operating in a digitally supportive virtual platform.
Authors: Dominic van Loggerenberg, Carol Benn
Journal: Journal of Clinical Oncology (2022)

e13645 Background: The BCCE is an NAPBC internationally accredited unit operating around a surgical oncology breast specialist surgeon, three reconstructive surgeons; four radiological units four pathology labs; 8 medical oncologists and 3 radiation oncologists. Whilst the centre was affected by the SARS Covid-19 pandemic, a rapid restructuring of the MDM procedure allowed for a return to -pre-pandemic service delivery and optimum time-to-treatment of 21days. Methods: Over the 2021 period the BCCE saw 778 newly diagnosed cancer patients, these are all reviewed at a 25 member MDM with 308 patients having full radiological review during the meetings and 609 full pathological reviews prior to treatment discussion amongst the members. These MDM discussions occurred within 6 days of clinical examination due to the integration of multiple specialists and facilities resulting in rapid appointments. Further pathological analysis of 203 patients occurred beyond initial presentation as well as over 350 OncotypeDx reviews. Five hundred and seventy-one individual patient treatment feedback discussions occurred directly postoperatively and 459 treatment plans were reviewed prior to secondary treatment pathways. Results: Digital MDM’s resulted in a full return to the centre’s optimum level of care, a 7 day MDM review with a 21-day treatment pathway plan proposal, whilst still under the effect of pandemic lockdown regulations. A 6-month comparison (during lockdown regulations) showed a 15% increase in patients seen whilst supported with virtual consultation platforms and digitally supported MDM decisions. Conclusions: Whilst the SARS Covid-19 pandemic affected service delivery. Medical IT transference to full digital MDM allowed for improved review and treatment planning. This improved service delivery to patients with physician and navigator knowledge transfer, resulting in growth of the unit.
Clinical features of patients with multiple myeloma harboring t(4;14) and impact on long-term survival.
Authors: Nisha Joseph, Craig C. Hofmeister, Leonard T. Heffner, Vikas Anand Gupta, Jonathan L. Kaufman, Madhav V. Dhodapkar, Sagar Lonial, Ajay K. Nooka, Lawrence Boise
Journal: Journal of Clinical Oncology (2022)

8062 Background: Translocation (4;14) is a known adverse prognostic factor in myeloma. However, utilization of proteasome inhibitors (PIs) in myeloma has abrogated the negative impact of t(4;14) in myeloma, and some investigators question whether t(4;14) still needs to be considered a high-risk marker. Here, we present a retrospective analysis of 142 patients with t(4;14) and describe disease characteristics, treatment patterns, and long-term outcomes. Methods: From January 2007 to August 2016, 42 patients with newly diagnosed myeloma and t(4;14) were identified. Demographics, clinical characteristics, and outcomes data for the patients were obtained from our institutional review board-approved myeloma database. Responses were evaluated per IMWG Uniform Response Criteria. Results: The median age of this cohort was 59.6 years (range 33-78). Notable patient characteristics include: W/AA/Asian 25.9%/23.6%/50%; ISS I/II/III 36.4%/22.9%/24.1%; R-ISS I/II/III 0%/27.8%/25.8%. Median lab values at diagnosis include: Hgb 10.4 g/dL, Hct 30.8%, Cr 1.01, and Ca 9.4, Frequency of concurrent cytogenetic abnormalities include del(17p): 19.7%; del(13): 44.4%, and +1q21: 46.5%. A majority of patients (86.7%) were induced with either triplet or quadruplet regimens, with 88% of these regimens including a proteasome inhibitor. 78.9% of patients underwent ASCT. Of those responses captured, 75.3% achieved ≥VGPR (sCR 4.8%, CR 30.5%, VGPR 40%, PR 20%). Post-transplant, 88% achieved ≥VGPR (sCR 35.1%, CR 30.9%, VGPR 22.3%), and 82% received maintenance therapy. The most common maintenance regimens included revlimid (34.8%), bortezomib (16.5%), and RVD (11.3%); one-third of patients received triplet maintenance regimens. With a median follow up of 99.5 months, the overall mPFS and mOS for this cohort of t(4;14) patients was 47.6 m (95% CI 32.3-62.8) and 108.5 months (95% CI 87.9-129.2). In patients with both t(4;14) and del(17p), the mPFS was 20.8 months and mOS was 89.6 months; for concurrent t(4;14) and +1q21, the mPFS was 32.0 months and 89.6 months. In patients that received maintenance therapy versus no maintenance, the mPFS and mOS was 54.9 months (95% CI 47.4-62.4) and 115.3 months (95% CI 96.3-134.3) versus 14.7 months (95% CI 13.1-16.3) and 34.3 months (95% CI 10.1-58.5), respectively. Conclusions: Overall, the prognosis of t(4;14) myeloma patients significantly improved compared to the pre-proteasome inhibitor era. In particular, maintenance therapies (predominantly PI- based) have made a clear survival impact (doubling of mPFS to 4.5 years and mOS to 9.5 years) compared to patients that did not receive maintenance therapy. However, presence of other concomitant cytogenetic abnormalities such as +1q21 and del(17p) continues to confer poorer outcomes, and innovative approaches are needed to obtain better outcomes for this subgroup of patients.
Generation and molecular characterization of paired human penile epithelial primary cell lines derived from patients with penile cancer
Authors: S. Broad, M. Hachim, T. Bertin, R. Hamoudi, B. Xiel, S. Khan, K. Penderecka, R. Henrique, N. Machulla, M. Arya, C. Thrasivolou, A. Ahmed, A. Muneer
Journal: European Urology (2022)
HGG-16. Final analysis of the HIT-HGG-2007 trial (ISRCTN19852453): Significant survival benefit for pontine and non-pontine pediatric high-grade gliomas in comparison to previous HIT-GBM-C/-D trials.
Authors: Andrè O von Bueren, Robert Kwiecien, Gerrit H Gielen, Martin Benesch, Thomas Perwein, Gunther Nussbaumer, Dominik Sturm, David T W Jones, Stefan M Pfister, Matthias Eyrich, Stefan Rutkowski, Gudrun Fleischhack, Miriam von Buiren, Michael Karremann, Rolf-Dieter Kortmann, Christian Hagel, Gabriele Calaminus, Andreas Faldum, Brigitte Bison, Torsten Pietsch, Marion Hoffmann, Christof M Kramm
Journal: Neuro-Oncology (2022)

Abstract The aim of the HIT-HGG-2007 trial (ISRCTN19852453) was to demonstrate therapeutic non-inferiority of temozolomide radiochemotherapy for pediatric patients (3-18 years) with high-grade gliomas (pedHGG) in comparison to the cisplatinum-based radiochemotherapy of the two previous clinical trials HIT-GBM-C/-D. Between 06/2009 and 12/2016, 456 patients were enrolled at 79 centers in Germany, Austria, and Switzerland (n=18 dropouts, remaining patients for confirmatory analysis: n=438). 438 patients from HIT-GBM-C/-D served as historical control. All pedHGG diagnoses had been confirmed by central neuroradiological and neuropathological review. Primary objective was achieved since non-inferiority of HIT-HGG-2007 in comparison to HIT-GBM-C/-D as indicated by 6 months event-free survival (EFS) was statistically confirmed (p=0.0125). Statistical survival analyses even revealed a better overall survival (OS) and EFS for HIT-HGG-2007 patients in comparison to their HIT-GBM-C/-D counterparts (EFS: p&amp;lt;0.0001; OS: p=0.0328). While EFS subgroup analyses for pontine and non-pontine pedHGG also showed a better survival of HIT-HGG-2007 patients (median EFS pontine pedHGG: 8.2 (n=152; confidence interval (CI): 7.6-9.4) versus 6.2 (n=170; CI: 5.5-6.9) months, p=0.0079; median EFS non-pontine pedHGG: 10.7 (n=276; CI: 9.6-12.4) versus 7.4 (n=267; CI: 6.4-9.2) months, p&amp;lt;0.0001), OS was only improved in HIT-HGG-2007 patients with non-pontine pedHGG (median OS non-pontine pedHGG: 19.3 (CI: 16.8-23.3) versus 16.2 (CI: 14.2-19.1) months; p=0.0181) but not with pontine pedHGG (median OS pontine pedHGG: 11.4 months versus 11.3 months, p=0.4021) Toxicity profile of HIT-HGG-2007 seemed very favorable with most CTCAE (common toxicity criteria adverse event) ≥ grade 3 as hematological toxicity, hepatotoxicity, and neurotoxicity. Less toxicity was observed during concomitant radiochemotherapy in comparison to HIT-GBM-C/-D. Further subgroup survival analyses as well as the assessment of the impact of MGMT promoter methylation are ongoing. In conclusion, our data show non-inferiority of the HIT-HGG-2007 trial with increased survival and less toxicity when compared with previous trials HIT-GBM-C/-D.
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study
Authors: Yuankai Shi, Gongyan Chen, Xiang Wang, Yunpeng Liu, Lin Wu, Yanrong Hao, Chunling Liu, Shuyang Zhu, Xiaodong Zhang, Yuping Li, Jiwei Liu, Lejie Cao, Ying Cheng, Hui Zhao, Shucai Zhang, Aimin Zang, Jiuwei Cui, Jian Feng, Nong Yang, Fei Liu, Yong Jiang, Chuan Gu
Journal: The Lancet Respiratory Medicine (2022)
Prospective randomized comparison of SP TFL for RIRS using 150-µm and 200-µm fibers for kidney stones: A single-center study
Authors: C. Azilgareeva, M. Taratkin, V. Petov, M. Enikeev, D. Korolev, G. Akopyan, A. Dymov, D. Chinenov, S. Ali, O. Traxer, D. Enikeev
Journal: European Urology (2022)
RARE-10. Neurocutaneous melanocytosis-associated hydrocephalus: the MSK experience from 2001-2022
Authors: Scarlett Rodriguez, Ugur Sener, Kevin Elmore, Sofia Haque, Stephanie Suser, Jeffrey Greenfield, Maria Donzelli, Courtnee DePass, John Pugh, Joanne Porter, Nathan Meeker, Elizabeth Wells, Ashfaq Marghoob, Yasmin Khakoo
Journal: Neuro-Oncology (2022)

Abstract OBJECTIVE: We hypothesize that patients with neurocutaneous melanocytosis-associated melanoma and ventriculoperitoneal shunts are at risk of developing intraperitoneal spread of melanoma. BACKGROUND: Neurocutaneous melanocytosis, a rare condition characterized by excessive proliferation and deposition of melanocytes in the leptomeninges and brain parenchyma, typically occurs in children with large congenital melanocytic nevi and multiple smaller congenital nevi. These patients are at heightened risk for developing NRAS+ melanomas in the central nervous system, which in turn may lead to symptomatic hydrocephalus requiring cerebrospinal fluid diversion for symptom relief. METHODS: Retrospective single-institution study of patients with histologically or radiographically confirmed NCM evaluated at Memorial Sloan Kettering Cancer Center (MSKCC) from 2001-2022. RESULTS: Of the 47 patients with a diagnosis of NCM, 44 patients had symptomatic neurological complications. Eleven patients developed hydrocephalus, 10 had CNS melanoma, and required ventriculoperitoneal shunt placement. Nine of the 10 patients ultimately died of their disease. Three patients were diagnosed with intraperitoneal melanoma, though data are unavailable for the remaining eight. CONCLUSIONS: All (n=11) patients with NCM-associated CNS melanoma required VP shunts for symptomatic relief. Ten of these patients died within 4.3 years of VP shunt placement, with a range of 1 month to 13.5 years prior to succumbing to their disease. While the intraperitoneal pathology remains unknown for 7 of the cases, 3 had confirmed intraperitoneal melanoma, suggesting that VP shunts provided the conduit to CNS melanoma seeding of the peritoneum. Obtaining baseline abdominal imaging studies prior to VP shunt placement may be helpful in the follow-up of these patients.
Perinephric toxic fat: Impact on surgical complexity, perioperative outcome and surgical approach in partial nephrectomy
Authors: M.T. Walach, F. Schiefelbein, A. Schneller, G. Schoen, C.A.J. Von Klot, J.K. Mühlbauer, P. Nuhn, M.C. Kriegmair, N.N. Harke
Journal: European Urology (2022)
Impact of the COVID-19 pandemic on stage at diagnosis of patients with breast cancer: An analysis of 11,752 patients from Oncoclínicas.
Authors: Cristiano Augusto Andrade de Resende, Rodrigo Dienstmann, Carlos H. Barrios, Bruno Lemos Ferrari, Aline Coelho Goncalves, Fanny Cascelli, Andreza Karine Souto, Matheus Costa e Silva, Heloisa Cruz, Leandro Carvalho Oliveira, Diocesio Alves Pinto de Andrade, Eduardo Camargo Millen, Felipe Zerwes, Tomas Reinert, Paulo Moraes, Max S. Mano
Journal: Journal of Clinical Oncology (2022)

10559 Background: As a reaction to the COVID-19 pandemic, a nation-wide lockdown was enforced in Brazil in March 2020, cancer care was impacted, and cancer screening reduced. Therefore, an increase in cancer diagnoses at more advanced stages was expected. In this study, we extracted data from our nationwide real-world database to evaluate the impact of the COVID-19 pandemic on the stage at diagnosis of breast cancer (BC) cases. Methods: We explored curated electronic medical record data of female patients, over 18 years of age, diagnosed with BC and with established disease stage based on the AJCC 8 th edition, who started treatment or follow-up in the Oncoclínicas (OC) between Jan 1, 2018, and Dec 31, 2021. The primary objective was to compare stage distribution at first visit during COVID-19 pandemic (2020-2021) with a historical control cohort from a period prior to the pandemic (2018-2019). We investigated stage distribution according to age at diagnosis and tumor ER/HER2 subtype in univariate models. Associations were considered significant if they had a minimum significance (P &lt; 0.1 in Chi-square test). The historical numbers of patients with BC at OC make it possible to identify differences in the prevalence of stages in the order of 5% comparing pre and post pandemic periods with a statistical power greater than 80%. Results: We collected data for 11,752 patients with initial diagnosis of BC, with 6,492 patients belonging to the pandemic (2020-2021) and 5,260 patients to the pre-pandemic period (2018-2019). For both ER+/ HER2- and HER2+ tumors, there was a lower percentage of patients with early-stage (defined as stage I-II) in the years 2020-2021 vs 2018-2019 and a considerable increase in advanced-stage disease (defined as stage IV). For triple negative BC (TNBC), there was a significant higher percentage of patients with advanced-stage disease in the pandemic vs pre-pandemic period (table 1). Age over 50 years was associated with a greater risk of advanced stage at diagnosis after the onset of the pandemic, with an absolute increase of 7% (P two-sided &lt;0.01) Conclusions: We observed a substantial increase in cases of advanced-stage BC in OC institutions as a result of delays in BC diagnoses due to the COVID-19 pandemic. The impact appeared greater in older adults, potentially because of stricter confinement in this group. [Table: see text]